Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
MX:INCY
Stock Latest News
Ratings
Incyte’s KRAS G12D Lead Supports Undervalued Upside as Kapoor Reiterates Buy and Maintains $152 Price Target
3d ago
INCY
Premium
The Fly
Incyte management to meet with Oppenheimer
4d ago
INCY
Premium
The Fly
Incyte price target raised to $123 from $120 at JPMorgan
4d ago
INCY
Premium
The Fly
MiniMed names Sheila Denton as General Counsel & Corporate Secretary
4d ago
INCY
MMED
Premium
Ratings
Incyte: Atebrioz Approval and KRAS Pipeline Upside Drive Buy Rating; Price Target Raised to $152
4d ago
INCY
Premium
The Fly
Mirum Pharmaceuticals, Incyte announce FDA approval of Atebrioz
7d ago
INCY
MIRM
Premium
The Fly
FDA approves Incyte’s Atebrioz for fibrodysplasia ossificans progressiva
7d ago
INCY
Premium
The Fly
Damora Therapeutics price target raised, named a Best Idea at Guggenheim
7d ago
DMRA
INCY
Premium
The Fly
Specialised Therapeutics expands partnership with Incyte to include Opzelura
12d ago
INCY
Premium
Company Announcements
Incyte Reaches CMS Pact on Jakafi Medicaid Pricing
1M ago
8K
INCY
Premium
Ratings
Buy Rating Reaffirmed on Incyte as ‘734 Pancreatic Cancer Data Looms; 12-Month Price Target Reiterated at $150
1M ago
INCY
Premium
The Fly
Incyte initiated with a Buy at Canaccord
1M ago
INCY
Premium
Ratings
Incyte Target Unchanged at $150 as Kapoor Reiterates Buy on Strong Early KRAS G12D Pancreatic Cancer Data
1M ago
INCY
Premium
Ratings
Matt Phipps Maintains Hold Rating on Incyte as Promising Early KRAS G12D PDAC Data Face Durability and Safety Uncertainties
1M ago
INCY
Premium
The Fly
Incyte ‘734 update likely to be ‘very competitive,’ says RBC Capital
1M ago
INCY
RVMD
Premium
The Fly
Incyte price target raised to $130 from $110 at Piper Sandler
2M ago
INCY
Premium
The Fly
Incyte price target raised to $104 from $99 at Bernstein
2M ago
INCY
Premium
Company Announcements
Incyte Earnings Call: Growth Surges, Costs Climb
2M ago
INCY
Premium
The Fly
Incyte price target raised to $137 from $121 at Mizuho
2M ago
INCY
Premium
The Fly
Incyte price target raised to $155 from $131 at Leerink
2M ago
INCY
Premium
Ratings
Analyst Reiterates Buy on Opzelura Strength, Keeps 12-Month Price Target Unchanged at $150
2M ago
INCY
Premium
The Fly
Incyte price target raised to $120 from $110 at JPMorgan
2M ago
INCY
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
